EPAS1 — gene · CancerIndex

Curated evidence

Clinical evidence (2)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
EPAS1 Overexpression2
(prognostic)	Malignant Colorectal NeoplasmCURATED_BROADER	Prognostic	B	Does Not Support Poor Outcome	3	accepted	EID1033 Expression of EPAS1 (HIF-2alpha) was assessed in 731 colorectal cancers from two prospective cohort studies. EPAS1 overexpression was found in 322 (46%) cancers by immunohistochemistry and not signifi… (full text at CIViC) PMID 20363910 · Baba et al., 2010 · Open in CIViC	civic
Pazopanib	Renal Cell CarcinomaCURATED_BROADER	Predictive	B	Does Not Support Sensitivity Response	2	accepted	EID1673 HIF2A (EPAS1) staining was conducted on tumors from 66 patients, of which 27 were classified as low expression and 39 were classified as high expression. The response rates of patients with low and hi… (full text at CIViC)

Cohorts

Alteration frequency by cohort (33)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved33 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Endometrial and Ovarian Cancer (MSK, Nature Medicine 2024) ucec_msk_2024	unmapped	Ssm	4	31	12.9%

Literature

Linked publications (2)

25 per page, newest first.

pubmedPublishedShowing 1–2 of 2 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers.
· Am J Pathol · 2010 · PMID 20363910 · validated civic_curation pubmed
The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.
· Clin Cancer Res · 2013 · PMID 23881929 · validated civic_curation pubmed